Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
Oil Prices Rise as Hormuz Tensions Threaten Global Supply 
ASX Faces Legal Action Over Failed Blockchain CHESS Project 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
US Dollar Holds Firm as Fed Outlook and Iran Tensions Keep Markets on Edge 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
OpenAI Executive Brad Lightcap to Leave for New AI Venture 
Samsung, SK Hynix Shares Surge on Report of Potential Temasek Investment 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Oil, Gold Rise as Geopolitical Risks Grip Markets Ahead of U.S. CPI 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Google Pushes Gemini AI Overhaul as Sergey Brin Targets Model Supremacy 
Canada, US Hold Fresh Trade Talks as August 19 Tariff Deadline Nears 
Gold Price Holds Near $4,400 as Hormuz Risks and CPI Drive Markets 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
SpaceX Shares Surge as Wall Street Backs AI Growth Potential 
Add as a preferred source on Google
Lotte Biologics has inked a memorandum of understanding (MOU) with Roche Diagnostics to bolster its Contract Development and Manufacturing Organization (CDMO) capabilities. This collaboration signifies major diagnostics, hardware, and automation advancements for Lotte's upcoming Korean production plants.
On Wednesday, Aug. 9, Lotte Biologics said it will work with Roche Diagnostics to improve the productivity and quality of its productions. The company said they would also team up to establish hardware and automation systems for Lotte's upcoming production plants in Korea, as per Korea Joongang Daily.
The MOU was signed at Roche Diagnostics CustomBiotech Center in Penzberg, Germany. Lotte Biologics' chief executive officer, Richard Lee; Roche Diagnostics CustomBiotech's vice president, Rainer Mueller; and Roche Diagnostics Korea's general manager, Kit Tang, were all present at the signing ceremony.
With the deal in place, Lotte Biologics aims to amplify its credibility with future global clients. The agreement will also serve as the forefront to underpin and shore up Roche Diagnostics' supply network in the Asian market. This will also give better treatment access to patients around the world.
"Through this MOU, we plan to enhance the production process capabilities of our Korean Mega Plant in collaboration with Roche Diagnostics," Lotte Biologics chief Richard Lee said in a press release. "Through synergy with Roche Diagnostics, an industry leader in the in vitro diagnostic field, LOTTE hopes to improve the efficiency of its operations at the forthcoming Korean Mega Plant, simultaneously augmenting the quality of our manufacturing and fulfilling customer needs."
Finally, Business Korea reported that Lotte Biologics and Roche Diagnostics will cooperate on various business fronts, including installing automation systems at the former's Mega Plants that will be built in Korea. The latter will also provide technical consulting and equipment support for the facilities.
Photo by: Lotte Biologics Newsroom
